📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Taysha Gene Therapies

1.1 - Company Overview

Taysha Gene Therapies Logo

Taysha Gene Therapies

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of gene therapies targeting severe, life-threatening monogenic diseases of the central nervous system, including TSHA-102 for Rett syndrome. Services include conducting clinical trials to assess safety and efficacy, offering an expanded access program for investigational therapies, advancing gene therapy research, and providing patient affairs support and educational resources with advocacy partnerships.

Products and services

  • TSHA-102 in Rett Syndrome: Engineers a CNS-targeted gene therapy product addressing Rett Syndrome, a monogenic CNS disease, aiming to eradicate severe, life‑threatening manifestations in affected patients
  • Gene Therapy Research: Develops monogenic-focused gene therapy products for diseases of the CNS, creating programs to advance treatments targeting rare neurological conditions with genetic causes
  • Clinical Trials: Conducts CNS-disorder-focused studies to assess safety and efficacy of gene therapy products, producing patient data that supports evaluation of therapeutic benefit and risk profiles

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Taysha Gene Therapies

U.S. WorldMeds Logo

U.S. WorldMeds

HQ: United States Website
  • Description: Provider of specialty pharmaceutical therapies: IWILFIN, an oral maintenance therapy reducing relapse risk in high-risk neuroblastoma after prior treatment response; ZIMHI, a high-dose naloxone injection for emergency treatment of opioid overdose, effective against powerful synthetic opioids like fentanyl; and LUCEMYRA, an oral drug that mitigates opioid withdrawal to facilitate abrupt discontinuation in adults.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full U.S. WorldMeds company profile →
SyntheticMR Logo

SyntheticMR

HQ: Sweden Website
  • Description: Provider of innovative magnetic resonance imaging software that supports shorter exam times and delivers more information to clinicians. Products include SyMRI NEURO for quantitative MRI with contrast images, tissue segmentation, and volumetric measurements in a single scan; SyMRI MSK for musculoskeletal imaging with quantitative maps and contrast images; and MAGiC, a GE Healthcare version offering customizable MRI imaging solutions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full SyntheticMR company profile →
Arthex Biotech Logo

Arthex Biotech

HQ: Spain Website
  • Description: Provider of antisense RNA and anti-miR therapies for Myotonic Dystrophy, including a program targeting upregulated miRNA to address the disease’s root cause and improve delivery to muscle tissue, and early preclinical development of an innovative Type 1 Myotonic Dystrophy drug with in vitro toxicity and preliminary pharmacokinetic and pharmacodynamic studies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arthex Biotech company profile →
Ad-Tech Medical Logo

Ad-Tech Medical

HQ: United States Website
  • Description: Provider of intra-cranial monitoring devices (electrodes) for the treatment of intractable epilepsy and neurosurgical instrumentation. Offerings include depth, subdural grid and strip, and foramen ovale electrodes for long-term EEG monitoring, mapping, SEEG, and intraoperative use; placement instruments and accessories for precise electrode placement; and connection systems to link electrodes to standard clinic EEG equipment.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ad-Tech Medical company profile →
Contineum Therapeutics Logo

Contineum Therapeutics

HQ: United States Website
  • Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Contineum Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Taysha Gene Therapies

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Taysha Gene Therapies

2.2 - Growth funds investing in similar companies to Taysha Gene Therapies

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Taysha Gene Therapies

4.2 - Public trading comparable groups for Taysha Gene Therapies

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Taysha Gene Therapies

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Taysha Gene Therapies

What does Taysha Gene Therapies do?

Taysha Gene Therapies is a provider of gene therapies targeting severe, life-threatening monogenic diseases of the central nervous system, including TSHA-102 for Rett syndrome. Services include conducting clinical trials to assess safety and efficacy, offering an expanded access program for investigational therapies, advancing gene therapy research, and providing patient affairs support and educational resources with advocacy partnerships.

Who are Taysha Gene Therapies's competitors?

Taysha Gene Therapies's competitors and similar companies include U.S. WorldMeds, SyntheticMR, Arthex Biotech, Ad-Tech Medical, and Contineum Therapeutics.

Where is Taysha Gene Therapies headquartered?

Taysha Gene Therapies is headquartered in United States.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies has 1,000 employees 🔒.

When was Taysha Gene Therapies founded?

Taysha Gene Therapies was founded in 2010 🔒.

What sector and industry vertical is Taysha Gene Therapies in?

Taysha Gene Therapies is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Taysha Gene Therapies

Who are the top strategic acquirers in Taysha Gene Therapies's sector and industry

Top strategic M&A buyers and acquirers in Taysha Gene Therapies's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Taysha Gene Therapies?

Top strategic M&A buyers groups and sectors for Taysha Gene Therapies include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Taysha Gene Therapies's sector and industry vertical

Which are the top PE firms investing in Taysha Gene Therapies's sector and industry vertical?

Top PE firms investing in Taysha Gene Therapies's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Taysha Gene Therapies's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Taysha Gene Therapies's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Taysha Gene Therapies's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Taysha Gene Therapies include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Taysha Gene Therapies's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Taysha Gene Therapies?

The key public trading comparables and valuation benchmarks for Taysha Gene Therapies include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Taysha Gene Therapies for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Taysha Gene Therapies with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Taysha Gene Therapies's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Taysha Gene Therapies with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Taysha Gene Therapies's' sector and industry vertical?

Access recent funding rounds and capital raises in Taysha Gene Therapies's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Taysha Gene Therapies